All questions
Clinical trials: Trulicity (dulaglutide) in type 2 diabetes 14 questions · 5 sources
Questions that apply to every indication of Trulicity are on Trulicity (dulaglutide), all indications .
Study results How quickly does Trulicity lower blood sugar after the first dose? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“6-week, multicenter, parallel-design, double-blind, part-randomized, placebo-controlled, multiple-dose, phase 1 study in patients ≥65 years old with type 2 diabetes treated with oral antihyperglycemic medications except sulfonylureas, disaccharidase inhibitors, and meglitinides
Study arms included placebo (n=8); Trulicity 0.5 mg (n=9), not a marketed dose; Trulicity 0.75 mg (n=11); and Trulicity 1.5 mg (n=9)
Primary objective was to evaluate the safety and tolerability of Trulicity 0.5 mg, 0.75 mg, and 1.5 mg for 6 weeks; mixed effect linear model; primary objective met
Data presented are LS mean change from baseline and are secondary endpoints” (opens the source at this quote in a new tab) Copy Flag
Note: The bar chart description is from the How Trulicity Works page; the study enrolled patients 65 years of age or older, and 0.5 mg is not a marketed dose.
How much does Trulicity lower A1C? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Note: Values are mean changes from baseline within each Trulicity group. The 3.0 mg and 4.5 mg values are from AWARD-11 at 36 weeks, described in the last two passages; differences from placebo or active comparators are in the trial-specific questions.
Do Trulicity 3 mg and 4.5 mg lower A1C more than 1.5 mg (AWARD-11)? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Table 6. Results at Week 36 of TRULICITY 1.5 mg Compared to 3 mg and 4.5 mg as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitusa
Abbreviations: HbA1c = hemoglobin A1c
a Intent-to-treat population. At Week 36, primary efficacy was missing for 7%, 7%, and 6% of individuals treated with TRULICITY 1.5 mg, TRULICITY 3 mg, and TRULICITY 4.5 mg, respectively.
b Least-squares mean adjusted for baseline value and other stratification factors. Missing data were imputed using multiple imputation.
c Patients with missing HbA1c data at Week 36 were considered as not achieving HbA1c target.
^ p=0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.
^^ p<0.0001 for superiority compared to TRULICITY 1.5 mg, overall type I error controlled.
36-Week Primary Time Point
TRULICITY
1.5 mg TRULICITY
3 mg TRULICITY
4.5 mg
Intent-to-Treat (ITT) Population (N) 612 616 614
HbA1c (%) (Mean)
Baseline 8.6 8.6 8.6
Change from baselineb -1.5 -1.6 -1.8
Difference from 1.5 mgb (95% CI) -0.1 (-0.2, 0.0) -0.2 (-0.4, -0.1) ^
Percentage of patients HbA1c <7.0% c 50 56 62
Fasting Serum Glucose (mg/dL) (Mean)
Baseline 185 184 183
Change from baselineb -45 -46 -51
Difference from 1.5 mgb (95% CI) - 2 (-7, 3) -6 (-11, -2)
Body Weight (kg) (Mean)
Baseline 95.5 96.3 95.4
Change from baselineb -3.0 -3.8 -4.6
Difference from 1.5 mgb (95% CI) -0.9 (-1.4, -0.4) -1.6 (-2.2, -1.1) ^^” (opens the source at this quote in a new tab) Copy Flag
Note: Table 6 columns are TRULICITY 1.5 mg, 3 mg, and 4.5 mg, in that order. The Trulicity HCP site identifies this dose-ranging trial as AWARD-11.
Does Trulicity lower A1C in moderate to severe chronic kidney disease? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Table 13: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro, in Patients with Moderate to Severe Chronic Kidney Disease in Adult Patients with Type 2 Diabetes Mellitusa
Abbreviation: HbA1c = hemoglobin A1c
a Intent-to-treat population (all randomized and treated patients) was used in the analysis regardless of discontinuation of study drug or initiation of rescue therapy. At Week 26, primary efficacy was missing for 12%, 15%, and 9% of individuals randomized to and treated with TRULICITY 0.75 mg, TRULICITY 1.5 mg, and insulin glargine, respectively. Missing data were imputed using multiple imputation within treatment group.
b Least-squares (LS) mean from ANCOVA pattern mixture model adjusted for baseline value and other stratification factors.
26-Week Primary Time Point
TRULICITY
0.75 mg TRULICITY
1.5 mg Insulin Glargine
Intent-to-Treat Population (N) 190 192 194
HbA1c (%) (Mean)
Baseline 8.6 8.6 8.6
Change from baselineb -0.9 -1.0 -1.0
Difference from insulin glargineb (95% CI) 0.0 (-0.2, 0.3) -0.1 (-0.3, 0.2)
Percentage of patients HbA1c <8.0% 73 75 74
Fasting Serum Glucose (mg/dL) (Mean)
Baseline 167 161 170
Change from baselineb 6 14 -23
Difference from insulin glargineb (95% CI) 30 (16, 43) 37 (24, 50)” (opens the source at this quote in a new tab) Copy Flag
Note: Table 13 columns are TRULICITY 0.75 mg, 1.5 mg, and insulin glargine, in that order; all arms also received insulin lispro.
How much weight do adults lose on Trulicity? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Note: The 36-week values are from AWARD-11, whose study description on the weight page of the Trulicity HCP site is the last passage.
Subgroup results Does Trulicity lower A1C more when baseline A1C is higher (AWARD-11)? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“The diagram shows the results of an exploratory post hoc subgroup analysis by baseline A1C range in adults with type 2 diabetes taking Trulicity. The results are presented in a bar chart that is separated by mean baseline A1C.
For patients who have an A1C baseline less than 8% receiving Trulicity 1.5 milligram (n=138), the mean reduction in A1C was 1% point from 7.6% to 6.6%. For patients receiving Trulicity 3.0 milligrams (n=148), the mean reduction in A1C was 1.2% points from 7.5% to 6.4%. For patients receiving Trulicity 4.5 milligrams (n=140), the mean reduction was 1.2% points from 7.6% to 6.4%.
For patients who have an A1C baseline between 8% and 9% receiving Trulicity 1.5 milligram (n=209), the mean reduction in A1C was 1.4% points from 8.4% to 7.0%. For patients receiving Trulicity 3.0 milligrams (n=216), the mean reduction in A1C was 1.6% points from 8.4% to 6.8%. For patients receiving Trulicity 4.5 milligrams (n=228), the mean reduction was 1.8% points from 8.4% to 6.6%.
For patients who have an A1C baseline between 9% and 10% receiving Trulicity 1.5 milligram (n=125), the mean reduction in A1C was 2.1% points from 9.4% to 7.3%. For patients receiving Trulicity 3.0 milligrams (n=101), the mean reduction in A1C was 2.2% points from 9.4% to 7.2%. For patients receiving Trulicity 4.5 milligrams (n=99), the mean reduction was 2.3% points from 9.4% to 7.1%.
For patients who have an A1C baseline greater than 10% receiving Trulicity 1.5 milligram (n=47), the mean reduction in A1C was 2.2% points from 10.4% to 8.3%. For patients receiving Trulicity 3.0 milligrams (n=55), the mean reduction in A1C was 2.5% points from 10.5% to 8.0%. For patients receiving Trulicity 4.5 milligrams (n=53), the mean reduction was 3.2% points from 10.4% to 7.2%.” (opens the source at this quote in a new tab) Copy Flag
Note: The first passage reports a prespecified subgroup analysis; the second describes a separate exploratory post hoc analysis by narrower baseline A1C ranges.
Long-term results Do Trulicity A1C reductions last 52 weeks (AWARD-11)? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Comparative studies Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
Note: Table 4 columns are TRULICITY 0.75 mg, 1.5 mg, and metformin 1500-2000 mg, in that order.
Trulicity vs sitagliptin: which lowers A1C more with metformin? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Table 5: Results at Week 52 of TRULICITY Compared to Sitagliptin used as Add-On to Metformin in Adult Patients with Type 2 Diabetes Mellitusa
Abbreviations: HbA1c = hemoglobin A1c.
a All ITT patients randomized after the dose-finding portion of the trial. Last observation carried forward (LOCF) was used to impute missing data. At Week 52 primary efficacy was missing for 15%, 19%, and 20% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.
b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 276, 277, and 270 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and sitagliptin, respectively.
†† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to sitagliptin, assessed only for HbA1c.
## p<0.001 TRULICITY compared to sitagliptin, assessed only for HbA1c <7.0%.
52-Week Primary Time Point
TRULICITY
0.75 mg TRULICITY
1.5 mg Sitagliptin
100 mg
Intent-to-Treat (ITT) Population (N)‡ 281 279 273
HbA1c (%) (Mean)
Baseline 8.2 8.1 8.0
Change from baselineb -0.9 -1.1 -0.4
Difference from sitagliptinb (95% CI) -0.5 (-0.7, -0.3)†† -0.7 (-0.9, -0.5)†† -
Percentage of patients HbA1c <7.0% 49## 59## 33
Fasting Plasma Glucose (mg/dL) (Mean)
Baseline 174 173 171
Change from baselineb -30 -41 -14
Difference from sitagliptinb (95% CI) -15 (-22, -9) -27 (-33, -20) -
Body Weight (kg) (Mean)
Baseline 85.5 86.5 85.8
Change from baselineb -2.7 -3.1 -1.5
Difference from sitagliptinb (95% CI) -1.2 (-1.8, -0.6) -1.5 (-2.1, -0.9) -” (opens the source at this quote in a new tab) Copy Flag
Note: Table 5 columns are TRULICITY 0.75 mg, 1.5 mg, and sitagliptin 100 mg, in that order.
Trulicity vs insulin glargine: how do A1C and weight compare? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Table 10: Results at Week 52 of TRULICITY Compared to Insulin Glargine, Both as Add-on to Metformin and Sulfonylurea in Adult Patients with Type 2 Diabetes Mellitusa
Abbreviations: HbA1c = hemoglobin A1c.
a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 52, primary efficacy was missing for 17%, 13% and 12% of individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg and glargine, respectively.
b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 267, 263 and 259 individuals randomized to TRULICITY 0.75 mg, TRULICITY 1.5 mg, and glargine, respectively.
52-Week Primary Time Point
TRULICITY
0.75 mg TRULICITY
1.5 mg Insulin Glargine
Intent-to-Treat (ITT) Population (N)‡ 272 273 262
HbA1c (%) (Mean)
Baseline 8.1 8.2 8.1
Change from baselineb -0.8 -1.1 -0.6
Fasting Serum Glucose (mg/dL) (Mean)
Baseline 161 165 163
Change from baselineb -16 -27 -32
Difference from insulin glargineb (95% CI) 16 (9, 23) 5 (-2, 12) -
Body Weight (kg) (Mean)
Baseline 86.4 85.2 87.6
Change from baselineb -1.3 -1.9 1.4
Difference from insulinb (95% CI) -2.8 (-3.4, -2.2) -3.3 (-3.9, -2.7) -” (opens the source at this quote in a new tab) Copy Flag
Note: Table 10 columns are TRULICITY 0.75 mg, 1.5 mg, and insulin glargine, in that order. All arms were add-on to maximally tolerated metformin and glimepiride.
Trulicity vs exenatide: how do A1C results compare? Applies to Glycemic control as an adjunct to diet and exercise in adults with type 2 diabetes mellitus
“Table 8: Results at Week 26 of TRULICITY Compared to Placebo and Exenatide, All as Add-On to Metformin and Thiazolidinedione in Adult Patients with Type 2 Diabetes Mellitusa
Abbreviations: BID = twice daily; HbA1c = hemoglobin A1c.
a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 23%, 10%, 7% and 12% of individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.
b Least-squares (LS) mean adjusted for baseline value and other stratification factors.
‡ Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 119, 269, 271 and 266 individuals randomized to placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide, respectively.
‡‡ Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to placebo, assessed only for HbA1c.
†† Multiplicity adjusted 1-sided p-value <0.001, for superiority of TRULICITY compared to exenatide, assessed only for HbA1c.
** p<0.001 TRULICITY compared to placebo, assessed only for HbA1c <7.0%.
## p<0.001 TRULICITY compared to exenatide, assessed only for HbA1c <7.0%.
26-Week Primary Time Point
Placebo TRULICITY
0.75 mg TRULICITY
1.5 mg Exenatide
10 mcg BID
Intent-to-Treat (ITT) Population (N)‡ 141 280 279 276
HbA1c (%) (Mean)
Baseline 8.1 8.1 8.1 8.1
Change from baselineb -0.5 -1.3 -1.5 -1.0
Difference from placebob (95% CI) - -0.8 (-1.0, -0.7)‡‡ -1.1 (-1.2, -0.9)‡‡ -
Difference from exenatideb (95% CI) - -0.3 (-0.4, -0.2)†† -0.5 (-0.7, -0.4)†† -
Percentage of patients HbA1c <7.0% 43 66**, ## 78**, ## 52
Fasting Serum Glucose (mg/dL) (Mean)
Baseline 166 159 162 164
Change from baselineb -5 -34 -42 -24
Difference from placebob (95% CI) - -30 (-36, -23) -38 (-45, -31) -
Difference from exenatideb (95% CI) - -10 (-15, -5) -18 (-24, -13) -
Body Weight (kg) (Mean)
Baseline 94.1 95.5 96.2 97.4
Change from baselineb 1.2 0.2 -1.3 -1.1
Difference from placebob (95% CI) - -1.0 (-1.8, -0.3) -2.5 (-3.3, -1.8) -
Difference from exenatideb (95% CI) - 1.3 (0.6, 1.9) -0.2 (-0.9, 0.4) -” (opens the source at this quote in a new tab) Copy Flag
Note: Table 8 columns are placebo, TRULICITY 0.75 mg, TRULICITY 1.5 mg, and exenatide 10 mcg twice daily, in that order.
Cardiovascular outcomes Does Trulicity lower the risk of heart attack, stroke, or CV death (REWIND)? Applies to Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
“Table 14: Treatment Effect for MACE and the Individual Components in the REWIND Trial, Median Trial Observation Time of 5.4 years in Adult Patients with Type 2 Diabetes Mellitusa
a All randomized patients.
b Cox-proportional hazards model with treatment as a factor. Type I error was controlled for the primary and secondary endpoints.
c p=0.026 for superiority (2-sided).
d Number and percentage of patients with events.
e Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity.
Time to First Occurrence of: TRULICITY
N=4949 Placebo
N=4952 Hazard Ratio
(95% CI)b
Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE)d 594 (12.0%) 663 (13.4%) 0.88 (0.79, 0.99)c
Cardiovascular deathd,e 317 (6.4%) 346 (7.0%) 0.91 (0.78, 1.06)
Non-fatal myocardial infarctiond,e 205 (4.1%) 212 (4.3%) 0.96 (0.79, 1.16)
Non-fatal stroked,e 135 (2.7%) 175 (3.5%) 0.76 (0.61, 0.95)
Fatal or non-fatal myocardial infarctiond,e 223 (4.5%) 231 (4.7%) 0.96 (0.79, 1.15)
Fatal or non-fatal stroked,e 158 (3.2%) 205 (4.1%) 0.76 (0.62, 0.94)” (opens the source at this quote in a new tab) Copy Flag
Note: Table 14 columns are TRULICITY (N=4949), placebo (N=4952), and the hazard ratio with its 95% CI.
Did Trulicity lower the risk of death in REWIND? Applies to Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
Note: The second passage is the cardiovascular death row of Table 14: TRULICITY, placebo, and the hazard ratio with its 95% CI. The Prescribing Information reports all-cause deaths as counts without a hazard ratio or statistical test; the cardiovascular death row is descriptive (footnote e), and its 95% CI includes 1.
Who was enrolled in the Trulicity REWIND cardiovascular outcomes trial? Applies to Reduction of the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors
“Multicenter, randomized, double-blind, placebo-controlled, event-driven trial designed to assess whether once-weekly Trulicity 1.5 mg safely reduces the incidence of cardiovascular (CV) outcomes compared to placebo in adult patients with type 2 diabetes with and without CVD
Key inclusion criteria: Established or newly detected type 2 diabetes with an A1C ≤9.5%; stable dose of up to 2 oral glucose-lowering drugs with or without basal insulin; BMI ≥23 kg/m2; age ≥50 years with established clinical vascular disease* , OR age ≥55 years and subclinical† vascular disease, OR age ≥60 years and at least 2 or more CV risk factors‡
Key exclusion criteria: Uncontrolled diabetes; severe hypoglycemia in preceding year; coronary or cerebrovascular event in preceding 2 months; plans to revascularize; estimated glomerular filtration rate (eGFR) <15 mL/min/1.73 m2 ; on dialysis; gastric bypass or emptying abnormality; prior pancreatitis; liver disease; family or personal history of C-cell hyperplasia, medullary thyroid cancer, multiple endocrine neoplasia (MEN) 2A or 2B, or calcitonin ≥20 pg/mL; unwilling to stop GLP-1 RA, dipeptidyl peptidase-4 (DPP-4) inhibitor, or weight loss drug; cancer within preceding 5 years; possible pregnancy; life expectancy <1 year
9901 patients were randomized to receive Trulicity 1.5 mg or same volume of placebo in addition to standard of care treatments such as oral antidiabetic treatments, insulin, and antihypertensive, antiplatelet, and lipid-lowering therapies; patients were assessed every 6 months until 1200 confirmed primary outcomes had accrued
Primary outcome was the first occurrence of the composite of either nonfatal MI, nonfatal stroke, or CV death (MACE-3). All outcomes occurring on or after randomization were included in analysis; Kaplan-Meier estimates were used to generate cumulative risks and Cox proportional hazard models were used to determine the effect of intervention on the outcome and to estimate HR and 95% CIs” (opens the source at this quote in a new tab) Copy Flag
“* History of myocardial infarction (MI), ischemic stroke, revascularization, hospitalization for unstable angina with concordant new ischemic electrocardiogram changes, or a positive stress test with concordant imaging.4
† Myocardial ischemia, coronary, carotid, or lower extremity artery stenosis exceeding 50%, ankle to brachial index <0.9, hypertension with left ventricular hypertrophy, eGFR <60 mL/min per 1.73m2 , or albuminuria.4
‡ Tobacco use, dyslipidemia, hypertension, or abdominal obesity.2 ” (opens the source at this quote in a new tab) Copy Flag